The 17 Beta Hydroxysteroid Dehydrogenase 13 pipeline drugs market research report outlays comprehensive information on the 17 Beta Hydroxysteroid Dehydrogenase 13 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the 17 Beta Hydroxysteroid Dehydrogenase 13 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Gastrointestinal which include the indications Metabolic Dysfunction-Associated Steatohepatitis (MASH), and Liver Fibrosis. It also reviews key players involved in 17 Beta Hydroxysteroid Dehydrogenase 13 targeted therapeutics development with respective active and dormant or discontinued products.

The 17 Beta Hydroxysteroid Dehydrogenase 13 pipeline targets constitutes close to eight molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, and Preclinical stages are 3, 1, and 4 respectively.

17 Beta Hydroxysteroid Dehydrogenase 13 overview

17 Beta-Hydroxysteroid dehydrogenase type 13 also known as 17Beta-HSD type 13 is an enzyme that in humans is encoded by a gene HSD17B13. HSD17B13 belongs to 17Beta-Hydroxysteroid dehydrogenases group of enzymes catalysing the conversion between 17-keto- and 17-hydroxysteroids. HSD17B13 is located on the surface of liver lipid droplets and its expression is markedly upregulated in the livers of patients and mice with non-alcoholic fatty liver disease (NAFLD) and enhances lipogenesis.

For a complete picture of 17 Beta Hydroxysteroid Dehydrogenase 13’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.